来那度胺在MM外应用sent.pptVIP

* * * * * * * * * * * * 淋巴结套区的CD5和CD20阳性小B细胞淋巴瘤； 主要免疫表型： CD5+CD19+; CD20+,CD22+/CD79β+, FMC7+, sIg++, λ k, HLA-DR+ 不表达CD10, CD23，Bcl-6 与SLL/CLL鉴别的鉴别要点 CD23-，FMC7+, CD22++/CD79β++, sIg++ * * * * * * * * * * * * Pegfilgrastim： 乙二醇化非格司亭，G-CSF Key Point This slide outlines the treatment regimen utilized in the study. Background Each 21-day cycle consisted of administration of rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1.4 mg/m2 on Day 1; prednisone 100 mg/m2 on Days 1-5, lenalidomide 15, 20, or 25 mg on Days 1-10, and 6 mg pegfilgrastim